TTK Healthcare Limited (TTKHLTCARE) Fair Value & Analysis
Healthcare · IN · Market cap ₹12.9B
Fair value as of: Jul 3, 2026
From 17 valuation models · updated today
Share price +0.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹739.60 – ₹1,353 · fair‑value band ₹592.64 – ₹987.74 · the ₹922.85 price screens above the ₹669.19 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
TTK Healthcare Limited (TTKHLTCARE) currently trades at ₹922.85, while our model-based Fair Value estimate is ₹669.19 — implying the stock looks roughly 27.5% overvalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, TTK Healthcare Limited generated revenue of ₹8.6B at a net margin of 7.7%. Revenue grew 14.5% year over year. It earns a return on equity of 6.0%. Net debt stands at ₹25.0M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and Others segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc. to veterinarians, dairy, poultry and aqua farmers, and pet parents. The Consumer Products segment is involved in the marketing and distribution of baby care products under the Woodward's Gripe water name; personal care products and cosmetics under the EVA name; home care products, such as scrubbers under the Good Home name; and air fresheners. The Medical Devices segment manufactures and markets artificial heart valves under the TTK Chitra name, as well as orthopedic implants and instruments for knee and hip replacements. The Protective …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
TTK Healthcare Limited reported revenue of ₹8.6B in FY2026 versus ₹6.0B in FY2022, a compound +9.4%/yr. Reported net income was ₹657M in FY2026, compounding +12.1%/yr from FY2022.
Is TTKHLTCARE fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,944 MXN | -29% |
| AbbVie Inc ABBV | $224.94 | $109.04 | -52% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| Merck & Co MRCK34 | R$72.90 | R$13.54 | -81% |
| AstraZeneca PLC A1ZN34 | R$157.11 | R$108.37 | -31% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TTK Healthcare Limited (TTKHLTCARE) undervalued?
What is the fair value of TTKHLTCARE?
What is the quality score of TTKHLTCARE?
What is the revenue of TTK Healthcare Limited (TTKHLTCARE)?
What is the net profit margin of TTKHLTCARE?
Does TTK Healthcare Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.